Loading...
Please wait, while we are loading the content...
Similar Documents
Gunstig langetermijneffect bij responders op interferonbehandeling onder patiënten met chronische hepatitis B in vergelijking tot non-responders; retrospectief onderzoek
| Content Provider | Semantic Scholar |
|---|---|
| Author | Zonneveld, Monika Van Honkoop, Pieter Hansen, Bettina E. Niesters, Hubert G. M. Murad, Sarwa Darwish Schalm, Solko W. Janssen, Hla |
| Copyright Year | 2005 |
| Abstract | Objective. To evaluate factors that influence clinical outcome and survival in chronic hepatitis-B patients treated with interferon alpha (IFNa). Design. Retrospective. Method. In a follow-up study of I65 hepatitis B e antigen (HBeAg)-positive patients who had been treated with IFNa in Rotterdam, the Netherlands, in I978-2002, data were collected on general patient characteristics, immunologic response, viral load, alanine aminotransferase (ALAT) activity, liver histology, occurrence of decompensated cirrhosis and hepatocellular carcinoma, and survival. Results. Median follow-up was 8.8 years (range: 0.3-23.9). 54 patients (33%) responded to IFNα treatment, defined as HBeAg loss within 12 months after the end of IFNa therapy. 52 percent of the responders lost hepatitis B surface antigen (HBsAg) as compared to 9% of the non-responders (p < 0.00I). Liver histology showed a decreased inflammatory activity and less progression of fibrosis in responders. Hepatocellular carcinoma was found in 8 patients, of whom 6 were non-responders. Of the 2 responders that developed hepatocellular carcinoma, I had relapsed after discontinuation of therapy. Multivariate analysis showed a significantly improved survival (relative risk (RR) of death: 0.28; 95% CI: 0.I0-0.78) and reduced risk of developing hepatocellular carcinoma (RR: 0.084; 95% CI: 0.0I-0.75) in responders. Conclusion. Response to IFNa therapy resulted in a prolonged clinical remission with an increased rate ofHBsAg seroconversion and improved liver histology. After correction for baseline factors, response to IFNα therapy was associated with increased survival and a reduced risk of developing hepatocellular carcinoma. |
| Starting Page | 1510 |
| Ending Page | 1515 |
| Page Count | 6 |
| File Format | PDF HTM / HTML |
| Volume Number | 149 |
| Alternate Webpage(s) | https://www.ntvg.nl/system/files/publications/2005115100001a.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |